Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
A 2013 study that analyzes IPO withdrawals between 1999 and 2004 found that about 13 percent returned later for a successful IPO, 36 percent turned again to raising capital privately, and 42 percent either merged or were acquired by other companies—another common strategy for biotechs. And about 11 percent filed bankruptcy.
Now that Bristol-Myers Squibb is acquiring Celgene, the company will largely disappear into Bristol-Myers Squibb, but a legacy of bold risk-taking and questionable price hikes remain.
Last year was a record year for biotech initial public offerings (IPOs), but 2019 is off to a slow and rocky start because of the government shutdown, which today is in its 31st day.
Kindred Biosciences, Inc. today announced the pricing of an underwritten public offering of 4,215,000 shares of its common stock at a public offering price of $9.50 per share
The two companies inked a non-disclosure agreement on December 22, 2018 and amended it a day later. One of the things apparent is that the companies wanted to make a splash at the JPM conference.
Mirati Therapeutics, Inc. (Nasdaq: MRTX) announced the pricing of an underwritten public offering of 1,612,903 shares of its common stock at a price to the public of $62.00 per share.
The third time may be the charm for Framingham, Mass.-based Alzheon when it comes to an initial public offering – because the company has balked the first two times it attempted to go public on the stock exchange.
In 2018 alone, mergers and acquisitions (M&A) activity among the life sciences industry totaled US$198B according to the 2019 EY M&A Firepower Report. The report continues on to state that “Life sciences M&A in 2018 was strong but failed to meet market expectations as companies focused on portfolio optimization.”
Despite the government shutdown, at least two biotech companies, Kaleido Biosciences and Cirius Therapeutics, have filed with the U.S. Securities and Exchange Commission (SEC) for initial public offerings (IPO).
With the JP Morgan Healthcare Conference ending today, it’s worth noting the word “healthcare” in the title, not “biopharma.” It’s not as if the biotech and pharmaceutical industry isn’t part of healthcare, but BioSpace’s reporting focuses on biopharma. Here’s a look at some of the more healthcare-oriented stories coming out of San Francisco this week.